Giuseppe Curigliano: Congratulations to Myriam Chalabi on her outstanding paper

Giuseppe Curigliano shared a post by NEJM on X:

“Congratulations to Myriam Chalabi on her outstanding paper! Your work highlights the incredible impact of creative women in science. Here’s to celebrating innovation and brilliance in every field!”

Quoting NEJM’s post:

“Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe. Read the full NICHE-2 phase 2 study results”

Source: Giuseppe Curigliano/X and NEJM/X

Giuseppe Curigliano, MD, PhD, is the Director of  the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology. He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues.

Myriam Chalabi is a Gastrointestinal Oncologist and clinician scientist at the Netherlands Cancer Institute in Amsterdam. In 2022 she was named one of the 11 early career researchers to watch by Nature Medicine. In 2023 she was awarded the ESMO José Baselga Fellowship for Clinician Scientists.